RecruitingNot ApplicableNCT05733416

Intensive Cancer Screening After Cryptogenic Stroke

Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial


Sponsor

Ottawa Hospital Research Institute

Enrollment

45 participants

Start Date

Sep 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study screens for hidden cancer in people who have had a cryptogenic stroke — a stroke where no clear cause was found despite thorough investigation. Emerging research suggests that some unexplained strokes may be caused by undetected cancers releasing blood clots. This study uses PET/CT scans to look for undiagnosed cancer in stroke patients within 3 months of their event. **You may be eligible if...** - You are 18 or older - You had a first-time ischemic stroke (a stroke caused by a blockage) with no clear cause found (cryptogenic stroke) - You have had this stroke within the past 3 months - You are being seen at the Ottawa Hospital - You (or a delegate) can provide informed consent **You may NOT be eligible if...** - You are pregnant or unable to lie still for 20 minutes (which is needed for the PET/CT scan) - You have a known current cancer or have previously been diagnosed with cancer (other than common skin cancers) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFDG PET/CT

F-fluorodeoxyglucose positron emission/computed tomography

DIAGNOSTIC_TESTUsual Care

Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care


Locations(1)

The Ottawa Hospital

Ottawa, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05733416


Related Trials